Evidence map›Paper›PMID 35838801›Full record

ArticleDiscover oncology2022

Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review.

Andreas Tartaglia, Giulia Busonero, Lorenza Gagliardi, Valentina Boddi, Federica Pieri, Maurizio Nizzoli

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Andreas TartagliaUnit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy. a.tartaglia@ausl.fo.it.
Giulia BusoneroUnit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy.
Lorenza GagliardiUnit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy.
Valentina BoddiUnit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy.
Federica PieriUnit of Pathology, Morgagni Hospital, Forlì, Italy.
Maurizio NizzoliUnit of Endocrinology and Metabolism, Morgagni Hospital, Via Carlo Forlanini 34, 47100, Forlì, Italy.
Carlo Forlanini Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperinsulinemic hypoglycemia is most commonly caused by a single, sporadic insulinoma. Multicentric insulinoma disease (insulinomatosis) as well as metachronous neuroendocrine tumors of the pancreas, known also as neuroendocrine adenomatosis, represent a very rare condition, if not associated with multiple endocrine neoplasia type 1 syndrome (MEN1) or Von Hippel Lindau disease. We report a 9-year follow-up of a 41-year-old woman, initially presenting with hypoglycemic syndrome caused by two insulin-producing tumors, who underwent subtotal pancreasectomy in 2012, with histology compatible with multiple small neuroendocrine tumors. An approximately 1-cm insulin-producing tumor recurred at subsequent biochemical and radiological follow-up, and was cured with the somatostatin analog octreotide as a single treatment, until remission of symptoms and complete regression of the pancreatic lesion achieved after only 16 months of treatment. The possible mechanisms for these findings are discussed and the literature is briefly reviewed.

Indexed as

HypoglycemiaMulticentric insulinomasPancreatic neuroendocrine tumorsSomatostatin analogs

Identifiers

PMID35838801
PMCPMC9287506
OpenAlexW4285491473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.